Trevi Therapeutics (TRVI) Stock News, May-Jul 2025

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming biotech conferences in August 2025. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough conditions, will be represented at Oppenheimer's 2025 Biotech in the Berkshires (August 4-6) and Stifel's 2025 Biotech Summer Summit (August 11-13).

President and CEO Jennifer Good will attend both events, with Chief Commercial Officer Farrell Simon joining for a fireside chat at the Stifel conference on August 11 at 1:00 p.m. ET.

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, announced its participation in the upcoming Leerink Partners Therapeutics Forum focused on I&I and Metabolism. The event will be held from July 8-9 in Boston, Massachusetts. The company's senior management, including President and CEO Jennifer Good and CFO Lisa Delfini, will be in attendance.

Trevi is currently developing Haduvio™ (oral nalbuphine ER), an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Trevi Therapeutics (NASDAQ: TRVI) has successfully closed its previously announced underwritten public offering, raising approximately $115.1 million before expenses. The offering included 20,010,000 shares of common stock priced at $5.75 per share, with underwriters fully exercising their option to purchase an additional 2,610,000 shares. The biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, conducted the offering through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering was made pursuant to a shelf registration statement on Form S-3 filed with the SEC.

Trevi Therapeutics (NASDAQ: TRVI) has announced the pricing of an underwritten public offering of 17.4 million shares of common stock at $5.75 per share, aiming to raise $100 million before deducting underwriting costs. The company, which is developing Haduvio for chronic cough in IPF and RCC patients, has also granted underwriters a 30-day option to purchase up to 2.61 million additional shares. The offering is expected to close around June 5, 2025, with Morgan Stanley, Leerink Partners, Stifel, and Cantor serving as joint book-running managers. The shares are being offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on August 15, 2023.

Trevi Therapeutics (NASDAQ: TRVI) has announced a proposed public offering of $100 million worth of common stock shares, with an additional 30-day option for underwriters to purchase up to $15 million more shares. The clinical-stage biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, will offer all shares through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering will be conducted under a previously filed shelf registration statement that was declared effective by the SEC on August 15, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Trevi Therapeutics (NASDAQ: TRVI) announced positive Phase 2b CORAL trial results for Haduvio in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The trial met its primary endpoint with significant reductions in 24-hour cough frequency across all dose groups, with the highest dose (108mg BID) achieving a -43.3% placebo-adjusted reduction. The drug demonstrated rapid efficacy at Week 2 and was well-tolerated, with similar discontinuation rates between treatment (5.6%) and placebo (5.0%) groups. Secondary endpoints showed significant improvements in cough severity and patient-reported outcomes. The company plans to meet with the FDA and initiate Phase 3 trials in first half of 2026.

Trevi Therapeutics (NASDAQ: TRVI) has scheduled a conference call and webcast for June 2nd, 2025, at 8:30 a.m. ET to present topline results from their Phase 2b CORAL trial. The trial evaluates Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The presentation will be accessible via webcast with audio and slides, and participants can join by phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). A 30-day replay will be available on the company's website after the event. Haduvio is also being investigated for refractory chronic cough (RCC) treatment.

Trevi Therapeutics (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, announced its participation in three major conferences in June 2025. The company will present at the American Cough Conference (June 6-7) discussing RIVER trial demographics for refractory chronic cough. At the CPDD 87th Annual Scientific Meeting (June 14-18), they will present research on nalbuphine's human abuse potential. Finally, at the BIO International Convention (June 16-19), the company will deliver a corporate presentation. Key executives, including CEO Jennifer Good and other senior management, will represent Trevi at these events.

Trevi Therapeutics (NASDAQ: TRVI) has presented additional analyses from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) for refractory chronic cough (RCC). The trial met its primary endpoint with a 67% reduction in 24-hour cough frequency from baseline and 57% on a placebo-adjusted basis (p0.0001)

Statistically significant responder analyses across all doses at 30%, 50%, and 75% thresholds

Significant improvement in Leicester Cough Questionnaire at Day 21

Adverse events were more common during initial exposure (27mg BID) but decreased over time

Most discontinuations occurred in first two weeks due to CNS and GI-related adverse events

The company awaits Phase 2b trial results in IPF patients with chronic cough to determine future development strategy.